To support guidance for clinicians, the National COVID-19 Clinical Evidence Taskforce, which includes a large coalition of peak health professional bodies will receive $1.5 million from the Medical Research Future Fund (MRFF) to ensure they are given the best possible advice on managing COVID-19 patients.
The Taskforce has been convened by the Australian Living Evidence Consortium, led by Cochrane Australia based in the School of Public Health and Preventive Medicine, Monash University. To provide front-line health care workers with the most up-to-date information and advice on the disease in a rapidly evolving environment. They will:
Analyse emerging national and international research and data on COVID-19.
Their recommendations will be continually reviewed and updated in near ‘real-time’.
The initial set of recommendations will be launched and will address priority topics in urgent need of clear and unified guidance, including:
Drug treatment of COVID-19 infection
Use of oxygen therapies
Key elements of critical care, and
Disease categories and monitoring.
Additional topics and recommendations for special populations will be added in the coming weeks.
This latest investment is in addition to the Government’s $2.4 billion corona virus National Health Plan that is providing support across primary care, aged care, hospitals, research and the National Medical Stockpile.
For the latest advice, information and resources, go to https://www.health.gov.au/
Feel free to contact us at firstname.lastname@example.org or (08) 9345 0499.